Compare Abeona Therapeutics Inc (ABEO) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.53. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | GPTY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $50.52 |
52-Week Low | $4.17 | $34.73 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GPTY trades at $44.83, up 3.15% in the last 24 hours, with technical indicators showing a bearish trend but oversold RSI signals. The ETF maintains a consistent weekly dividend payout strategy, with recent distributions ranging from $0.30 to $0.38. News highlights focus on its AI and tech portfolio exposure and option-income strategy, though technical momentum remains weak.
Outlook is mixed: high dividend yield and AI theme appeal to income investors, but bearish technicals and reliance on semiconductor momentum pose risks. Investor sentiment is cautious amid volatile tech sector performance, requiring close monitoring of NAV stability and market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
